Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.38 |
| ▸ | CA2 | P00918 | 17/20 | 0.38 |
| ▸ | MMP1 | P03956 | 7/20 | 0.38 |
| ▸ | MMP2 | P08253 | 7/20 | 0.38 |
| ▸ | MMP9 | P14780 | 7/20 | 0.38 |
| ▸ | MMP8 | P22894 | 7/20 | 0.38 |
| ▸ | MMP13 | P45452 | 7/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771806 | 0.98 | CA2 (0.40) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5950044 | 0.83 | CA2 (0.34) | CA1CA2HSD11B1 | |
| SCHEMBL5851106 | 0.82 | CA1 (0.36) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6331113 | 0.81 | CA2 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1419588 | 0.77 | CA1 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6479936 | 0.73 | CA2 (0.45) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6336252 | 0.72 | KMT2A (0.44) | HSD11B1 | |
| Iodide SCHEMBL5315919 | 0.71 | PIK3CD (0.44) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6900759 | 0.71 | CA2 (0.46) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL27366575 | 0.71 | PIK3CD (0.44) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2045275-B1 | Polycyclic resist compositions with increased etch resistance | SUMITOMO BAKELITE CO (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20090093114-A1 | METHOD OF FORMING A DUAL-DAMASCENE STRUCTURE USING AN UNDERLAYER | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2009-04-09 | — | — | US | disclosed |
| EP-2045275-A2 | Polycyclic resist compositions with increased etch resistance | Sumitomo Bakelite Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7335787-B2 | Method for producing onium salt derivatives, and novel onium salt derivatives | TOYO GOSEI KOGYO CO., LTD. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-20050176982-A1 | Method for producing onium salt derivatives, and novel onium salt derivatives | TOYO GOSEI KOGYO CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6620957-B1 | Process for producing onium salt derivative and novel onium salt derivative | TOYO GOSEI KOGYO CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| US-6451499-B1 | Polycyclic resist compositions with increased etch resistance | THE B.F. GOODRICH COMPANY | 2002-09-17 | — | — | US | disclosed |
| EP-1164127-A1 | PROCESS FOR PRODUCING ONIUM SALT DERIVATIVE AND NOVEL ONIUM SALT DERIVATIVE | Toyo Gosei Kogyo Co., Ltd. (JP) | 2001-12-19 | — | — | EP | disclosed |
| EP-1058699-A1 | POLYCYCLIC RESIST COMPOSITIONS WITH INCREASED ETCH RESISTANCE | THE B.F. GOODRICH COMPANY (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6147177-A | POLYCYCLIC POLYOLEFIN COMPRISING MONOMER(S) HAVING AROMATIC MOIETIES; RADIATION TRANSPARENT TO DEEP UV WAVELENGTHS FOR HIGH RESOLUTION PHOTOLITHOGRAPHY | THE B. F. GOODRICH COMPANY (US) | 2000-11-14 | — | — | US | disclosed |
| WO-1999042502-A1 | POLYCYCLIC RESIST COMPOSITIONS WITH INCREASED ETCH RESISTANCE | THE B.F. GOODRICH COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176982-A1 | Method for producing onium salt derivatives, and novel onium salt derivatives | STS, NANS, GRIK5 | CA1 118/4885CA2 6/4885MMP1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.